Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1

Interventions

Specimen Handling 27Magnetic Resonance Spectroscopy 23Cyclophosphamide 16Biopsy 16Doxorubicin 13pembrolizumab 11Temozolomide 11X-Rays 10Radiation 10atezolizumab 8Radiotherapy 8Irinotecan 8Phantoms, Imaging 7Nivolumab 7fludarabine 6Vincristine 6Immunoglobulin G 6Etoposide 6Bevacizumab 6liposomal doxorubicin 5cemiplimab 5cabozantinib 5Sirolimus 5Ifosfamide 5Gemcitabine 5Disulfides 5palbociclib 4olaparib 4fludarabine phosphate 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
IDRX-42 × Sarcoma × 30 days × Clear all
NCT07218926 2026-05-27

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

GlaxoSmithKline

Phase 3 Recruiting
450 enrolled
GastrointestinalSarcoma

Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡